CytomX Therapeutics, Inc.
CTMX
$0.9284
-$0.1616-14.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 2,155.20% | 91.71% | -501.10% | 516.52% | 109.54% |
| Total Depreciation and Amortization | -15.02% | -11.36% | -24.75% | -21.51% | -20.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 75.19% | 668.94% | -7.33% | -42.14% | -65.14% |
| Change in Net Operating Assets | -68.69% | -30.73% | 43.18% | -501.65% | -899.48% |
| Cash from Operations | 9.36% | -13.63% | 22.36% | -378.59% | -1,476.67% |
| Capital Expenditure | 69.92% | -111.11% | 81.43% | -139.58% | -46.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.86% | 142.37% | -18.64% | 130.70% | -86.87% |
| Cash from Investing | 17.64% | 142.31% | -17.39% | 130.61% | -87.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 821.72% | -- | 1,508.52% | -- | 28.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 821.72% | -100.00% | 1,508.52% | -- | 28.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.49% | 91.87% | 498.98% | 113.85% | -108.98% |